Skip to main content
. 2016 Dec 20;34(2):495–512. doi: 10.1007/s12325-016-0464-9

Table 5.

Median overall survival in months: all patients (stage IIIB–IV M1c)

Drug Unadjusted Modified Korn adjustment
Dacarbazinea 9.3 NA
GM-CSF 18.9 14.2
gp100 6.4 7.3

GM-CSF granulocyte-macrophage colony-stimulating factor, gp100 glycoprotein 100, NA not applicable

aObserved median overall survival (based on pooled analysis of four dacarbazine curves)